Sign In
Buy TXG
$47.27
-2.16 (-4.37%)
At Close: Jul 31, 2026
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
04:05pm, Tuesday, 11'th Nov 2025
PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate i
10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
10:56pm, Thursday, 06'th Nov 2025
10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO &
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics
08:01pm, Thursday, 06'th Nov 2025
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics c
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates
06:56pm, Thursday, 06'th Nov 2025
10x Genomics (TXG) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
10x Genomics Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
PLEASANTON, Calif. , Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September�
Torex Gold Resources Inc. (TXG:CA) Q3 2025 Earnings Call Transcript
11:56am, Thursday, 06'th Nov 2025
Torex Gold Resources Inc. ( TXG:CA ) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants Dan Rollins - Senior Vice President of Corporate Development & Investor Relations Jody Kuze
10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:07am, Thursday, 30'th Oct 2025
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday
02:42am, Thursday, 30'th Oct 2025
10x Genomics (NASDAQ: TXG - Get Free Report) will likely be announcing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.27
10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
09:00am, Wednesday, 29'th Oct 2025
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif. , Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, In
Lancaster Opens $7 Million Position in 10x Genomics (TXG)
12:25pm, Friday, 24'th Oct 2025
Lancaster Investment Management bought over 620,000 shares in 10x Genomics (TXG) worth around $7.27 million. 10x Genomics, a new holding for the investment manager, now accounts for 3.1% of its AUM.
10x Genomics (TXG) Moves 11.1% Higher: Will This Strength Last?
06:21am, Tuesday, 21'st Oct 2025
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
12:30pm, Monday, 20'th Oct 2025
Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader
Blue Trust Inc. Raises Holdings in 10x Genomics $TXG
03:40am, Sunday, 19'th Oct 2025
Blue Trust Inc. increased its position in shares of 10x Genomics (NASDAQ: TXG) by 48.1% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns
12:05pm, Friday, 17'th Oct 2025
From Red Robin to Analog Devices, these five high-efficiency stocks stand out for their strong ratios and surprise earnings potential.
10x Genomics (TXG) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Thursday, 16'th Oct 2025
10x Genomics (TXG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
